These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
276 related items for PubMed ID: 29173064
21. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O, PanCareLIFE consortium. Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960 [Abstract] [Full Text] [Related]
22. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin. Spracklen TF, Vorster AA, Ramma L, Dalvie S, Ramesar RS. Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817 [Abstract] [Full Text] [Related]
24. [Genetic background of cisplatin induced ototoxicity]. Jurajda M, Talach T, Kostřica R, Lakomý R, Kocák I, Cvanová M. Klin Onkol; 2012 Dec; 25(3):184-7. PubMed ID: 22724567 [Abstract] [Full Text] [Related]
25. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, Pakakasama S, Hongeng S. J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376 [Abstract] [Full Text] [Related]
26. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. Vos HI, Guchelaar HJ, Gelderblom H, de Bont ES, Kremer LC, Naber AM, Hakobjan MH, van der Graaf WT, Coenen MJ, te Loo DM. Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270 [Abstract] [Full Text] [Related]
28. [Research progress on the relationship between cisplatin ototoxicity and autophagy]. Liang Z, Cheng G, Zhang T, Jia H. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Feb; 34(2):189-192. PubMed ID: 32086932 [Abstract] [Full Text] [Related]
29. Ototoxicity: bioprotective mechanisms. Rybak LP, Kelly T. Curr Opin Otolaryngol Head Neck Surg; 2003 Oct; 11(5):328-33. PubMed ID: 14502062 [Abstract] [Full Text] [Related]
32. Aminoglycoside ototoxicity in Nicaraguan children: patient risk factors and mitochondrial DNA results. Saunders JE, Greinwald JH, Vaz S, Guo Y. Otolaryngol Head Neck Surg; 2009 Jan; 140(1):103-7. PubMed ID: 19130971 [Abstract] [Full Text] [Related]
33. Clinical evaluation and mitochondrial DNA sequence analysis in two Chinese families with aminoglycoside-induced and non-syndromic hearing loss. Zhao L, Wang Q, Qian Y, Li R, Cao J, Hart LC, Zhai S, Han D, Young WY, Guan MX. Biochem Biophys Res Commun; 2005 Oct 28; 336(3):967-73. PubMed ID: 16168391 [Abstract] [Full Text] [Related]
34. Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. Li Z, Li R, Chen J, Liao Z, Zhu Y, Qian Y, Xiong S, Heman-Ackah S, Wu J, Choo DI, Guan MX. Hum Genet; 2005 Jun 28; 117(1):9-15. PubMed ID: 15841390 [Abstract] [Full Text] [Related]
35. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, Chen Y, Zou Z. Eur J Pharm Biopharm; 2021 Jun 28; 163():60-71. PubMed ID: 33775853 [Abstract] [Full Text] [Related]
37. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Ratain MJ, Cox NJ, Henderson TO. Clin Pharmacol Ther; 2013 Dec 28; 94(6):631-5. PubMed ID: 24241639 [Abstract] [Full Text] [Related]
38. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children. Siemens A, Brooks B, Rassekh SR, Meijer AJM, van den Heuvel-Eibrink MM, Xu W, Loucks CM, Ross CJD, Carleton BC, Canadian Pharmacogenomics Network for Drug Safety Consortium. Ther Drug Monit; 2023 Jun 01; 45(3):345-353. PubMed ID: 36917731 [Abstract] [Full Text] [Related]
39. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR, CPNDS Consortium. Nat Genet; 2009 Dec 01; 41(12):1345-9. PubMed ID: 19898482 [Abstract] [Full Text] [Related]
40. Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides. Chen KS, Bach A, Shoup A, Winick NJ. Pediatr Blood Cancer; 2013 Nov 01; 60(11):1772-7. PubMed ID: 23788258 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]